Oramed Pharmaceuticals Stock Buy Hold or Sell Recommendation
| ORMP Stock | USD 2.37 0.02 0.85% |
Given the investment horizon of 90 days and your way above-average risk tolerance, our recommendation regarding Oramed Pharmaceuticals is 'Cautious Hold'. Macroaxis provides Oramed Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ORMP positions. The advice algorithm takes into account all of Oramed Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Oramed Pharmaceuticals' buy or sell advice are summarized below:
Real Value 2.68 | Target Price 3.15 | Hype Value 2.36 | Market Value 2.37 | Naive Value 2.02 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Oramed Pharmaceuticals given historical horizon and risk tolerance towards Oramed Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Oramed Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Oramed |
Execute Oramed Pharmaceuticals Buy or Sell Advice
The Oramed recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Oramed Pharmaceuticals. Macroaxis does not own or have any residual interests in Oramed Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Oramed Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Oramed Pharmaceuticals Trading Alerts and Improvement Suggestions
| Oramed Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.7 M. Net Loss for the year was (37.76 M) with profit before overhead, payroll, taxes, and interest of 2.7 M. | |
| Oramed Pharmaceuticals currently holds about 133.91 M in cash with (27.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Oramed Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Head to Head Contrast CASI Pharmaceuticals versus Oramed Pharmaceuticals - Defense World |
Oramed Pharmaceuticals Returns Distribution Density
The distribution of Oramed Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Oramed Pharmaceuticals' future price movements. The chart of the probability distribution of Oramed Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Oramed Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Oramed Pharmaceuticals returns is essential to provide solid investment advice for Oramed Pharmaceuticals.
| Mean Return | 0.19 | Value At Risk | -5.41 | Potential Upside | 8.96 | Standard Deviation | 4.69 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Oramed Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Oramed Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Oramed Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oramed Pharmaceuticals backward and forwards among themselves. Oramed Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Oramed Pharmaceuticals' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Qube Research & Technologies | 2023-12-31 | 86.5 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 64.2 K | State Street Corporation | 2023-12-31 | 58 K | Susquehanna International Group, Llp | 2023-12-31 | 45.9 K | Lpl Financial Corp | 2023-12-31 | 43.2 K | Jpmorgan Chase & Co | 2023-12-31 | 28.8 K | Pnc Financial Services Group Inc | 2023-12-31 | 26.2 K | Geode Capital Management, Llc | 2023-12-31 | 25.5 K | American Century Companies Inc | 2023-12-31 | 19.3 K | Bml Capital Management Llc | 2023-12-31 | 1.3 M | Murchinson Ltd. | 2023-12-31 | 1.1 M |
Oramed Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (1.7M) | 16.0M | 57.9M | 13.0M | 15.0M | 15.7M | |
| Free Cash Flow | (13.0M) | (12.5M) | (21.6M) | (28.4M) | (25.6M) | (24.3M) | |
| Capital Expenditures | 15K | 82K | 375K | 496K | 570.4K | 598.9K | |
| Net Income | (11.5M) | (23.0M) | (36.6M) | (37.8M) | (34.0M) | (32.3M) | |
| Other Non Cash Items | 38K | 1.0M | 22K | (778K) | (700.2K) | (665.2K) | |
| End Period Cash Flow | 3.3M | 19.3M | 77.2M | 40.5M | 46.5M | 48.9M | |
| Depreciation | 8K | 7K | 77K | 58K | 52.2K | 54.8K | |
| Investments | 8.5M | 1.6M | 30.7M | 9.6M | 11.1M | 11.7M | |
| Change To Netincome | 1.1M | 1.8M | 2.3M | 9.5M | 11.0M | 11.5M |
Oramed Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Oramed Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Oramed Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Oramed stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.02 | |
β | Beta against NYSE Composite | 1.84 | |
σ | Overall volatility | 4.77 | |
Ir | Information ratio | 0.02 |
Oramed Pharmaceuticals Volatility Alert
Oramed Pharmaceuticals shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Oramed Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Oramed Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Oramed Pharmaceuticals Fundamentals Vs Peers
Comparing Oramed Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Oramed Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Oramed Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Oramed Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Oramed Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Oramed Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Oramed Pharmaceuticals to competition |
| Fundamentals | Oramed Pharmaceuticals | Peer Average |
| Return On Equity | 0.0324 | -0.31 |
| Return On Asset | -0.0516 | -0.14 |
| Profit Margin | 4.12 % | (1.27) % |
| Operating Margin | (11.77) % | (5.51) % |
| Current Valuation | (16.94 M) | 16.62 B |
| Shares Outstanding | 40.52 M | 571.82 M |
| Shares Owned By Insiders | 11.20 % | 10.09 % |
| Shares Owned By Institutions | 13.86 % | 39.21 % |
| Number Of Shares Shorted | 583.94 K | 4.71 M |
| Price To Earning | (11.22) X | 28.72 X |
| Price To Book | 0.62 X | 9.51 X |
| Price To Sales | 76.20 X | 11.42 X |
| Revenue | 2.7 M | 9.43 B |
| Gross Profit | 2.7 M | 27.38 B |
| EBITDA | (36.98 M) | 3.9 B |
| Net Income | (37.76 M) | 570.98 M |
| Cash And Equivalents | 133.91 M | 2.7 B |
| Cash Per Share | 3.45 X | 5.01 X |
| Total Debt | 894 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 21.01 X | 2.16 X |
| Book Value Per Share | 4.06 X | 1.93 K |
| Cash Flow From Operations | (27.92 M) | 971.22 M |
| Short Ratio | 3.95 X | 4.00 X |
| Earnings Per Share | 0.14 X | 3.12 X |
| Target Price | 4.25 | |
| Beta | 1.82 | -0.15 |
| Market Capitalization | 95.22 M | 19.03 B |
| Total Asset | 161.64 M | 29.47 B |
| Retained Earnings | (163.08 M) | 9.33 B |
| Working Capital | 109.37 M | 1.48 B |
| Current Asset | 31 M | 9.34 B |
| Current Liabilities | 4 M | 7.9 B |
Note: Acquisition by Reznick Yehuda of 29800 shares of Oramed Pharmaceuticals subject to Rule 16b-3 [view details]
Oramed Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Oramed . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 2.37 | |||
| Day Typical Price | 2.37 | |||
| Price Action Indicator | 0.01 | |||
| Period Momentum Indicator | 0.02 | |||
| Relative Strength Index | 30.9 |
About Oramed Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Oramed Pharmaceuticals? Buying financial instruments such as Oramed Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Total Current Liabilities | 6.5K | 5.7M | 6.6M | 6.9M | Other Current Liabilities | 70.0 | 2.0M | 2.3M | 2.4M |
Use Investing Ideas to Build Portfolios
In addition to having Oramed Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run World Allocation Funds Thematic Idea Now
World Allocation Funds
Funds or Etfs investing in stocks, bonds, and cash of domestic markets as well as in markets of Canada, Japan, and Europe. The World Allocation Funds theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize World Allocation Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Oramed Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Oramed Stock analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Oramed Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oramed Pharmaceuticals. If investors know Oramed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oramed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.14 | Revenue Per Share 0.033 | Quarterly Revenue Growth (1.00) | Return On Assets (0.05) | Return On Equity 0.0324 |
The market value of Oramed Pharmaceuticals is measured differently than its book value, which is the value of Oramed that is recorded on the company's balance sheet. Investors also form their own opinion of Oramed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oramed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oramed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oramed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oramed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oramed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oramed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.